Futura Medical plc announce headline results from its efficacy study of the Company's novel gel for the treatment of erectile dysfunction
Posted:
21
September 2016
<p></p>
Futura Medical plc announce headline results from its efficacy study of the Company's novel gel for the treatment of erectile dysfunction
The study comprised a total of 232 randomised males and it measured, as its primary endpoint, improvement in the erectile function ("EF") domain score of the International Index of Erectile Function ("IIEF"), the scoring system used for the approval of PDE5 inhibitors such as Viagra®. The study was of a placebo-controlled, double blind, home use, crossover design.View news article
Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations
April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Richmond Pharmacology announces CEO Dr. Jorg Taubel's appointment as President Elect of Germany's AGAH, where he will enhance early-phase clinical research over a six-year term.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.